Document Detail


Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
MedLine Citation:
PMID:  17384500     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play an important role in the atherosclerosis. Recombinant human erythropoietin (EPO) has become widely used to treat anemic hemodialyzed (HD) patients; however, an increased mortality has been reported for HD patients with cardiovascular disease when randomly assigned to normal hematocrit by EPO. Therefore, we conducted a study examining the effect of EPO on MMPs/TIMPs system, oxidative stress and inflammation in these patients. METHODS: Assessment of MMP-2, MMP-9, TIMP-1 and TIMP-2 were performed in 20 stable HD patients and 15 healthy controls. Additionally, the effects of EPO on malondialdehyde (MDA)--a marker of SOX and C-reactive protein (CRP) levels--as a marker of inflammation were also investigated. Of the 20 patients, 10 were receiving EPO therapy [HD-EPO(+)] for 12 months or more and 10 were not receiving EPO therapy [HD-EPO(-)]. Both groups were not receiving iron supplementation. RESULTS: All parameters, with the exception of MMP-9, were lower in the healthy subjects compared with the HD subjects, irrespective of EPO administration. There was no difference in MMPs/TIMPs system, MDA and C-reactive levels between HD-EPO(+) and HD-EPO(-) patients. CONCLUSION: Erythropoietin therapy did not influence MMPs/TIMPs system, inflammation, or SOX in a low-risk HD patient population, in the absence of concomitant iron supplementation and mean Hg levels within target.
Authors:
Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Publication Detail:
Type:  Journal Article     Date:  2007-03-23
Journal Detail:
Title:  American journal of nephrology     Volume:  27     ISSN:  1421-9670     ISO Abbreviation:  Am. J. Nephrol.     Publication Date:  2007  
Date Detail:
Created Date:  2007-05-30     Completed Date:  2007-06-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8109361     Medline TA:  Am J Nephrol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  221-5     Citation Subset:  IM    
Copyright Information:
2007 S. Karger AG, Basel
Affiliation:
Department of Nephrology and Clinical Transplantation, Medical University, Bialystok, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anemia / drug therapy
C-Reactive Protein / metabolism*
Case-Control Studies
Erythropoietin / administration & dosage,  adverse effects*
Female
Humans
Male
Malondialdehyde / blood
Metalloproteases / blood,  drug effects*
Middle Aged
Oxidative Stress / drug effects*
Renal Dialysis / adverse effects*
Tissue Inhibitor of Metalloproteinases / blood,  drug effects*
Uremia / therapy
Chemical
Reg. No./Substance:
0/Tissue Inhibitor of Metalloproteinases; 11096-26-7/Erythropoietin; 542-78-9/Malondialdehyde; 9007-41-4/C-Reactive Protein; EC 3.4.-/Metalloproteases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Brainstem epidermoid cyst in a child. Case report.
Next Document:  A prospective study to compare subcutaneously buried peritoneal dialysis catheter technique with con...